| Autor: |
Kallieri, Maria, Papaioannou, Andriana I., Zervas, Eleftherios, Fouka, Evangelia, Porpodis, Konstantinos, Hadji Mitrova, Marija, Tzortzaki, Eleni, Makris, Michael, Ntakoula, Maria, Lyberopoulos, Panagiotis, Dimakou, Katerina, Koukidou, Sofia, Ampelioti, Sevasti, Papaporfyriou, Anastasia, Katsoulis, Konstantinos, Kipourou, Maria, Rovina, Nikoletta, Antoniou, Katerina, Vittorakis, Stylianos, Bakakos, Petros |
| Předmět: |
|
| Zdroj: |
Clinical & Experimental Allergy; Apr2024, Vol. 54 Issue 4, p286-290, 5p |
| Abstrakt: |
This article presents a post hoc analysis of the RELight study, which investigated the clinical benefit of switching from omalizumab to mepolizumab in patients with severe asthma. The study found that patients who switched to mepolizumab experienced a reduction in asthma exacerbations, improved asthma control, and a decrease in oral corticosteroid intake. These improvements were observed regardless of whether the patients had previously received omalizumab treatment. The findings suggest that switching therapies may be beneficial for patients with severe asthma who do not achieve optimal disease control. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text